PMID- 23725567
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20130603
IS  - 1744-7623 (Electronic)
IS  - 1472-8214 (Linking)
VI  - 18
IP  - 2
DP  - 2013 Jun
TI  - Emerging tyrosine kinase inhibitors for esophageal cancer.
PG  - 219-30
LID - 10.1517/14728214.2013.805203 [doi]
AB  - INTRODUCTION: Because of the poor prognosis for patients with esophagogastric 
      cancers (EGCs), increasing attention has focused on targeted agents. AREAS 
      COVERED: Targets include epidermal growth factor receptor (EGFR), vascular 
      endothelial growth factor (VEGF), Her2, mammalian target of rapamycin (mTOR), and 
      MET. We briefly discuss preclinical data and the rationale for targeting these 
      pathways and summarize the results of clinical trials of tyrosine kinase 
      inhibitors (TKIs) against these targets. EXPERT OPINION: While anti-EGFR therapy 
      has been extensively investigated, completed Phase III trials suggest that this 
      is not a promising target. A Phase III trial of an anti-VEGF antibody failed to 
      show improvement in the primary endpoint of overall survival but response rates 
      and progression-free survival were improved; a Phase III trial of an anti-VEGF 
      receptor 2 antibody in second-line therapy did show improved survival. As such, 
      Phase II and III evaluations of anti-VEGF TKIs are ongoing. The only Food and 
      Drug Administration-approved targeted therapy in EGC is trastuzumab, an anti-Her2 
      antibody, and the results of a Phase III evaluation of lapatinib, an anti-Her2 
      TKI, are awaited. Phase III evaluation of an mTOR inhibitor has been negative. 
      Finally, MET inhibition appears to have significant clinical potential and early 
      testing of MET TKIs is underway.
FAU - Ku, Geoffrey Y
AU  - Ku GY
AD  - Memorial Sloan-Kettering Cancer Center, Department of Medicine, Gastrointestinal 
      Oncology Service, 300 East 66th Street, New York, NY 10065, USA.
FAU - Ilson, David H
AU  - Ilson DH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Emerg Drugs
JT  - Expert opinion on emerging drugs
JID - 101135662
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Esophageal Neoplasms/*drug therapy
MH  - Humans
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/*antagonists & inhibitors
EDAT- 2013/06/04 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/06/04 06:00 [entrez]
PHST- 2013/06/04 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
AID - 10.1517/14728214.2013.805203 [doi]
PST - ppublish
SO  - Expert Opin Emerg Drugs. 2013 Jun;18(2):219-30. doi: 
      10.1517/14728214.2013.805203.